Immucor seeks FDA nod for blood bank technology:
This article was originally published in Clinica
Executive Summary
Immucor, a provider of automated instrument-reagent systems to the blood transfusion industry, has submitted a 510(k) marketing application to the US FDA for its Galileo instrument. The product is a high-throughput, highly automated blood bank system. It was launched in Europe in mid 2002. Edward Gallup, the Norcross, Georgia firm's chairman and CEO, said that "at the end of November 2003, the company had 93 placements."
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.